Reuters logo
6 个月前
BRIEF-Abeona Therapeutics provides update from phase 1/2 MPS IIIA clinical trial
2017年2月17日 / 下午1点10分 / 6 个月前

BRIEF-Abeona Therapeutics provides update from phase 1/2 MPS IIIA clinical trial

Feb 17 (Reuters) - Abeona Therapeutics Inc:

* Abeona Therapeutics provides update from ABO-102 phase 1/2 MPS IIIA clinical trial at the 13th Annual Worldsymposium 2017

* Abeona Therapeutics Inc - ABO-102 gene therapy well-tolerated in 4 subjects through 650 days follow up with no serious adverse events

* Abeona Therapeutics Inc - enrollment of high-dose cohort is underway Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below